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INTRODUCTION
Currently a large number of generic drugs are 
registered in Ukraine for medical use. The advantage 
of generic drugs is the relatively cheapness compared 
to innovative medicines, because the creation and 
registration of generic drugs require less research 
and, consequently, less material costs, which are nec-
ABSTRACT
PURPOSE: Study of dissolution profiles of nifedipine tablets from different manufacturers to further as-
sess of their equivalence in vitro, as well as study of the dependence of the dissolution profile on the adju-
vants composition.
MATERIAL AND METHODS: 3 buffer media with pH 1.2 (hydrochloric acid buffer); 4.5 (acetate buffer); 6.8 
(phosphate buffer) was used. The absorptions were observed at 343.
RESULTS: The dissolution profiles of nifedipine tablets from different manufacturers have been studied 
and have been founded that the percentage of nifedipine release from the sample B is higher than from 
“Corinfar”, and the percentage of nifedipine release from “Corinfar” is higher than from the sample A. Ad-
juvants composition of nifedipine tablets have been studied. It is founded that the inclusion of surfactants, 
solubilizers and emulsifiers into tablets contribute to increasing of active substance release from the dos-
age form.
CONCLUSIONS: Found that the introduction of surfactants into tablets, solubilizers and emulsifiers help to 
increase the release of active substance from the dosage form.
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essary in the development, research and market in-
troduction of a new original drugs (6-9).
The equivalence of the efficacy and safety of in-
novative and generic drugs ensures their therapeutic 
equivalence (11). Currently abroad for some generic 
drugs estimate of interchangeability may be set on 
the basis of comparative tests in vitro, which includes 
the study of biopharmaceutical properties of medic-
inal substances, examination of adjuvants composi-
tion, determining the dissolution rate and evaluation 
of dissolution profiles equivalence (1-4,13,14).
Aim of the work. Study of dissolution profiles 
of nifedipine tablets from different manufacturers to 
further assess of their equivalence in vitro, as well as 
study of the dependence of the dissolution profile on 
the adjuvants composition.
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MATERIAL AND METHODS
The study included two samples of select-
ed drugs nifedipine of different composition from 
Ukrainian producers, sample A and sample B, 10 mg 
tablets. As a reference drug used “Corinfar” 10 mg 
tablets. Selecting of the reference product was con-
ducted in accordance with the requirements of the 
WHO recommend primarily used as a comparator 
the original drugs (4,14).
Comparative study of the kinetics of dissolu-
tion was carried out in accordance with the WHO’s 
requirements using 3 buffer media with pH 1.2 (hy-
drochloric acid buffer); 4.5 (acetate buffer); 6.8 (phos-
phate buffer) and in accordance with the require-
ments of the Manual of Clinical Trials “Investiga-
tion of Bioavailability and Bioequivalence” (5). All 
buffer solutions were prepared in accordance with 
SPhU (12). pH of the solution was measured by pH 
meter pH 150MI, if necessary the pH was adjusted to 
the desired value. Test “Dissolution” was performed 
in the apparatus by Pharma Test (Germany) “Device 
with basket” (temperature - 37 °C, the rate of rota-
tion of the vane - 75 rev/min, the volume of dissolu-
tion medium - 900 ml).
In the glasses 1 tablet of each of the nifedipine 
medicines respectively were placed for dissolving. Se-
quential sampling was performed at 15, 30, 45 min 
in the volume of 10 ml, same volume of buffer solu-
tion was added to the dissolution medium for main-
taining of volume. Obtained samples were allowed to 
stand at room temperature in a dark place for 20-30 
min, then filtered through a paper filter. To obtain 
statistically reliable results, the study was carried out 
by 6 times for each drug.
The content of extracted active substance was 
determined by UV spectrophotometry. The absor-
bance of samples was measured with a spectropho-
tometer Evolution 60S at a wavelength of 343 nm in a 
cuvette with a layer thickness of 10 mm. Simultane-
ously, the absorbance of standard solution of nifedip-
ine at a concentration of 0.02 mg/ml in an appropri-
ate buffer was measured. As the comparison solution 
served the same buffer solution, which was used as 
dissolution medium.
RESULTS
To determine the character of the absorption 
spectrum were removed ultraviolet spectra of the 
standard sample (SS) of nifedipine in all buffer me-
dia at a concentration of active substance of 0.02 mg/
ml. Fig. 1 shows an absorption spectrum in hydro-
chloric acid , acetate and phosphate buffer solutions, 
peaks are observed at the wavelengths 239 nm and 
343 nm. The absorption spectra of the extracts of the 
investigational drugs tablet mass in the same buffer 
solutions were identical.
As a result of this experiment releasing pro-
files of nifedipine tablets of samples A and B, and of 
the original drug “Corinfar” were obtained. Accord-
ing to the analysis of obtained data (Fig. 2-4), nife-
dipine sufficiently rapidly goes into solution: after 15 
minutes released not less than 70% of the active sub-
stance, then the dissolution process was dramatically 
slowed. As it often happens, the most significant dif-
ferences between the release profiles were observed 
at the beginning of the test after 15 minutes. The de-
pendence of release rate on pH of dissolution medi-
um was observed: the release rate increased with in-
creasing of pH.
Fig. 1. Ultraviolet absorption spectrum of nifedipine SS in 
hydrochloric buffer (1), acetate buffer (2) and phosphate 
buffer (3)
Fig. 2. Profiles of comparative dissolution kinetics of nife-
dipine medicines in hydrochloric acid buffer (pH 1.2)
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DISCUSSION
From the data obtained by the dissolution pro-
files (Figs. 2-4) it is evident that at pH =1.2, sam-
ple B and “Corinfar” have identical dissolution pro-
files. The percentage of maximum release of nife-
dipine for 90 minutes was about 60%, while the per-
centage of nifedipine release from sample A was very 
low – 48.74%. With increasing pH values to 4.5 the 
percentage of nifedipine released from the sample 
B was increased to 85%, releasing from “Corinfar” 
was somewhat worse – 75%, and from the sample A 
– 63%. In phosphate buffer solution, there was a no-
ticeable increasing of the release of nifedipine from 
all three samples: the sample B – 92%, “Corinfar” – 
88%, the sample A – 78%.
Seeing that the dissolution profile of sample B is 
better than the original drug “Corinfar” and the dis-
solution profile of the sample A is significantly worse, 
we decided to study the tablet composition in order 
to find the dependence of the dissolution profiles on 
the adjuvants composition. In the table 1 set the com-
position of adjuvants of samples A, B and “Corinfar” 
tablets. From table 1 shows that the compositions of 
sample B and “Corinfar” are similar, except that the 
composition of sample B includes a combination of 
Tween-80 with sodium laurylsulfate, and “Corinfar” 
- Macrogol 35000. Sodium laurylsulfate is anion-
ic surfactant which in combination with emulsifier 
Tween-80 promotes the dissolution of poorly soluble 
in water nifedipine. Therefore, releasing of nifedipine 
from the sample B passes noticeably better. The com-
position of “Corinfar” includes a combination of film 
formers Macrogol 6000 and Macrogol 35000, which 
are polyethyleneglycols (non-aqueous solvent, a sol-
ubilizer) and during the dissolution process they in-
crease the solubility and the percentage of nifedipine 
release, so the release profile of “Corinfar” is better 
than the profile of sample A.
Fig. 3. Profiles of comparative dissolution kinetics of nife-
dipine medicines in acetate buffer (pH 4.5)
Fig. 4. Profiles of comparative dissolution kinetics of nife-
dipine medicines in phosphate buffer (pH 6.8)















Table 1. Adjuvants composition of nifedipine tablets
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CONCLUSIONS
The dissolution profiles of nifedipine tablets 
from different manufacturers have been studied and 
have been founded that the percentage of nifedip-
ine release from the sample B is higher than from 
“Corinfar”, and the percentage of nifedipine release 
from “Corinfar” is higher than from the sample A.
Adjuvants composition of nifedipine tablets 
have been studied. It is founded that the inclusion of 
surfactants, solubilizers and emulsifiers into tablets 
contribute to increasing of active substance release 
from the dosage form.
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